(via NewsDirect)
The data points to an excellent safety profile and promising signs of clinical activity, with 60% of patients who reached the six-month mark showing improved bone marrow fibrosis scores.
“PXS-5505 continues to show not only an excellent safety profile but also promising clinical activity,”
“The effect on bone marrow fibrosis is particularly exciting for a disease like myelofibrosis, where despite numerous years of research, we do not have any effective anti-fibrotic drugs.
“It is encouraging to see that majority of 10 patients who completed 24 weeks of therapy also had improvements of symptoms and more importantly, stable or improved blood counts; including in those patients with severe thrombocytopenia.”
Contact Details
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source